Altinicline

Altinicline (SIB-1508Y, SIB-1765F) is a drug which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype.^[1][2] It stimulates release of dopamine and acetylcholine in the brain in both rodent and primate models,^[3] and progressed as far as Phase II clinical trials for Parkinson's disease,^[4] where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.

Altinicline

Clinical data
ATC code	None
Identifiers
IUPAC name (2S)-3-ethynyl-5-(1-methylpyrrolidin-2-yl)pyridine
CAS Number	179120-92-4 Y
PubChem CID	3036156
ChemSpider	2300234 Y
UNII	RJ9V9V09VM
ChEMBL	ChEMBL111659 Y
CompTox Dashboard (EPA)	DTXSID40870143
Chemical and physical data
Formula	C12H14N2
Molar mass	186.258 g·mol−1
3D model (JSmol)	Interactive image
SMILES c2ncc(C#C)cc2C1CCCN1C
InChI InChI=1S/C12H14N2/c1-3-10-7-11(9-13-8-10)12-5-4-6-14(12)2/h1,7-9,12H,4-6H2,2H3/t12-/m0/s1 Y Key:NUPUDYKEEJNZRG-LBPRGKRZSA-N Y
(verify)